Literature DB >> 16758579

Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia.

J R López1, L Alamo, C Caputo, J Wikinski, D Ledezma.   

Abstract

Ca2+ selective microelectrodes have been used to determine the free myoplasmic [Ca2+] in human skeletal muscle obtained from patients who had developed early signs associated with malignant hyperthermia (MH) during anesthesia. Intercostal muscle biopsies were performed under local anesthesia in four MH patients 15 days to 4 months after developing the MH crisis and in three control subjects. We used only microelectrodes that showed a Nernstian response between pCa3 and pCa7 (30.5 mV per decade at 37 degrees C). Membrane resting potential (V(m)) and calcium potential (V(Ca)) were obtained from superficial fibers. The free cytosolic [Ca2+] was 0.39 +/- 0.1 microM (mean +/- SEM, n = 18) in muscle fibers obtained from malignant hyperthermic patients, whereas in control subjects it was 0.11 +/- 0.02 microM (n = 10). These results suggest that this syndrome might be related to an abnormally high myoplasmic free resting calcium concentration, probably due to a defective function of the plasma membrane or the sarcoplasmic reticulum.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 16758579     DOI: 10.1002/mus.880080502

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

1.  Resting calcium concentrations in isolated skeletal muscle fibres of dystrophic mice.

Authors:  D A Williams; S I Head; A J Bakker; D G Stephenson
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

2.  Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

Authors:  K E Keating; L Giblin; P J Lynch; K A Quane; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 3.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

4.  Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers.

Authors:  S J Healy; J J Heffron; M Lehane; D G Bradley; K Johnson; T V McCarthy
Journal:  BMJ       Date:  1991-11-16

5.  Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.

Authors:  J R Lopez; V Kaura; C P Diggle; P M Hopkins; P D Allen
Journal:  Br J Anaesth       Date:  2018-08-10       Impact factor: 9.166

6.  Ca2+ influx via the Na+/Ca2+ exchanger is enhanced in malignant hyperthermia skeletal muscle.

Authors:  Francisco Altamirano; José M Eltit; Gaëlle Robin; Nancy Linares; Xudong Ding; Isaac N Pessah; Paul D Allen; José R López
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

Review 7.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

8.  Junctional membrane Ca2+ dynamics in human muscle fibers are altered by malignant hyperthermia causative RyR mutation.

Authors:  Tanya R Cully; Rocky H Choi; Andrew R Bjorksten; D George Stephenson; Robyn M Murphy; Bradley S Launikonis
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

9.  A malignant hyperthermia-inducing mutation in RYR1 (R163C): alterations in Ca2+ entry, release, and retrograde signaling to the DHPR.

Authors:  Eric Estève; José M Eltit; Roger A Bannister; Kai Liu; Isaac N Pessah; Kurt G Beam; Paul D Allen; José R López
Journal:  J Gen Physiol       Date:  2010-05-17       Impact factor: 4.086

10.  Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia.

Authors:  José M Eltit; Xudong Ding; Isaac N Pessah; Paul D Allen; José R Lopez
Journal:  FASEB J       Date:  2012-11-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.